Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01289990
First received: January 31, 2011
Last updated: July 14, 2014
Last verified: July 2014
Results First Received: May 16, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double-Blind;   Primary Purpose: Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773
Drug: Placebo
Drug: Sitagliptin 100mg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Empagliflozin 10 mg (Drug Naive)

Patients rolled over from trial 1245.20

Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Drug Naive)

Patients rolled over from trial 1245.20

Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Drug Naive)

Patients rolled over from trial 1245.20

Placebo tablets matching Empagliflozin / Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 25 mg

Sitagliptin 100mg (Drug Naive)

Patients rolled over from trial 1245.20

Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 25 mg

Placebo: Placebo matching Empagliflozin 10 mg

Sitagliptin 100mg: Sitagliptin once daily

Empagliflozin 10 mg (Pioglitazone)

Patients rolled over from trial 1245.19

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Pioglitazone)

Patients rolled over from trial 1245.19

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Pioglitazone)

Patients rolled over from trial 1245.19

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg (Metformin)

Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg: Empagliflozin 10 mg once daily

Empagliflozin 25 mg (Metformin)

Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Metformin)

Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg


Participant Flow:   Overall Study
    Empagliflozin 10 mg (Drug Naive)   Empagliflozin 25 mg (Drug Naive)   Placebo (Drug Naive)   Sitagliptin 100mg (Drug Naive)   Empagliflozin 10 mg (Pioglitazone)   Empagliflozin 25 mg (Pioglitazone)   Placebo (Pioglitazone)   Empagliflozin 10 mg (Metformin)   Empagliflozin 25 mg (Metformin)   Placebo (Metformin)   Empagliflozin 10 mg (Metformin+Sulfonylurea)   Empagliflozin 25 mg (Metformin+Sulfonylurea)   Placebo (Metformin+Sulfonylurea)
STARTED   224   224   228   223   165   168   166   217   214   207   226   218   225 
COMPLETED   147   143   119   136   93   94   78   162   139   121   150   150   127 
NOT COMPLETED   77   81   109   87   72   74   88   55   75   86   76   68   98 
Death                0                0                0                1                2                1                0                0                0                0                0                1                0 
Lost to Follow-up                3                2                5                5                3                4                2                2                1                4                2                1                2 
Withdrawal by Subject                15                14                12                13                8                7                13                9                12                13                11                13                16 
discontinued in preceding trial                18                20                41                17                11                12                18                8                17                21                17                17                24 
did not continue in extension                41                45                51                51                48                50                54                36                44                48                45                34                56 
Not treated                0                0                0                0                0                0                1                0                1                0                1                2                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full Analysis Set (FAS): which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial.

Reporting Groups
  Description
Empagliflozin 10 mg (Drug Naive)

Patients rolled over from trial 1245.20

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Drug Naive)

Patients rolled over from trial 1245.20

Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Sitagliptin

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Drug Naive)

Patients rolled over from trial 1245.20

Placebo tablets matching Empagliflozin / Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching Empagliflozin 25 mg

Sitagliptin 100 mg (Drug Naive)

Patients rolled over from trial 1245.20

Sitagliptin once daily

Placebo: Placebo matching Empagliflozin 25 mg

Placebo: Placebo matching Empagliflozin 10 mg

Sitagliptin 100 mg: Sitagliptin once daily

Empagliflozin 10 mg (Pioglitazone)

Patients rolled over from trial 1245.19

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Pioglitazone)

Patients rolled over from trial 1245.19

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Pioglitazone)

Patients rolled over from trial 1245.19

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg (Metformin)

Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg: Empagliflozin 10 mg once daily

Empagliflozin 25 mg (Metformin)

Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Metformin)

Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 10 mg (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Empagliflozin 10 mg tablets once daily

Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily

Placebo: Placebo matching Empagliflozin 25 mg

Empagliflozin 25 mg (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Empagliflozin 25 mg tablets once daily

Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily

Placebo: Placebo matching Empagliflozin 10 mg

Placebo (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Placebo tablets matching Empagliflozin

Placebo: Placebo matching Empagliflozin 10 mg

Placebo: Placebo matching Empagliflozin 25 mg

Total Total of all reporting groups

Baseline Measures
   Empagliflozin 10 mg (Drug Naive)   Empagliflozin 25 mg (Drug Naive)   Placebo (Drug Naive)   Sitagliptin 100 mg (Drug Naive)   Empagliflozin 10 mg (Pioglitazone)   Empagliflozin 25 mg (Pioglitazone)   Placebo (Pioglitazone)   Empagliflozin 10 mg (Metformin)   Empagliflozin 25 mg (Metformin)   Placebo (Metformin)   Empagliflozin 10 mg (Metformin+Sulfonylurea)   Empagliflozin 25 mg (Metformin+Sulfonylurea)   Placebo (Metformin+Sulfonylurea)   Total 
Overall Participants Analyzed 
[Units: Participants]
 224   224   228   223   165   168   165   217   213   207   225   216   225   2700 
Age 
[Units: Years]
Mean (Standard Deviation)
 56.2  (11.6)   53.8  (11.6)   54.9  (10.9)   55.1  (9.9)   54.7  (9.9)   54.2  (8.9)   54.6  (10.5)   55.5  (9.9)   55.6  (10.2)   56.0  (9.7)   57.0  (9.2)   57.4  (9.3)   56.9  (9.2)   55.6  (10.2) 
Gender 
[Units: Participants]
                           
Female   82   79   105   82   82   83   92   92   93   91   112   102   113   1208 
Male   142   145   123   141   83   85   73   125   120   116   113   114   112   1492 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]

2.  Primary:   Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

3.  Secondary:   HbA1c (%) Changes From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

4.  Secondary:   Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]
  Hide Outcome Measure 4

Measure Type Secondary
Measure Title Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Measure Description Systolic blood pressure - change from baseline after 52 weeks of treatment
Time Frame Baseline and 52 weeks  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline systolic blood pressure assessment, irrespective of participation in the extension trial. (LOCF)

Reporting Groups
  Description
BI 10773 Low (Drug Naive)

Patients rolled over from trial 1245.20

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching BI 10773 high dose

BI 10773 High (Drug Naive)

Patients rolled over from trial 1245.20

BI 10773 tablets once daily

Placebo: Placebo matching Sitagliptin

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 low dose

Placebo (Drug Naive)

Patients rolled over from trial 1245.20

Placebo tablets matching BI 10773 / Sitagliptin once daily

Placebo: Placebo matching BI 10773 low dose

Placebo: Placebo matching Sitagliptin

Placebo: Placebo matching BI 10773 high dose

Sitagliptin 100mg (Drug Naive)

Patients rolled over from trial 1245.20

Sitagliptin once daily

Placebo: Placebo matching BI 10773 high dose

Placebo: Placebo matching BI 10773 low dose

Sitagliptin 100mg: Sitagliptin once daily

BI 10773 Low (Pioglitazone)

Patients rolled over from trial 1245.19

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 high dose

BI 10773 High (Pioglitazone)

Patients rolled over from trial 1245.19

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 low dose

Placebo (Pioglitazone)

Patients rolled over from trial 1245.19

Placebo tablets matching BI 10773 once daily

Placebo: Placebo matching BI 10773 low dose

Placebo: Placebo matching BI 10773 high dose

BI 10773 Low (Metformin)

Patients rolled over from trial 1245.23

BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 high dose

BI 10773: BI 10773 tablets once daily

BI 10773 High (Metformin)

Patients rolled over from trial 1245.23

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 low dose

Placebo (Metformin)

Patients rolled over from trial 1245.23

Placebo tablets matching BI 10773 once daily

Placebo: Placebo matching BI 10773 low dose

Placebo: Placebo matching BI 10773 high dose

BI 10773 Low (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 high dose

BI 10773 High (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

BI 10773 tablets once daily

BI 10773: BI 10773 tablets once daily

Placebo: Placebo matching BI 10773 low dose

Placebo (Metformin+Sulfonylurea)

Patients rolled over from trial 1245.23

Placebo tablets matching BI 10773

Placebo: Placebo matching BI 10773 low dose

Placebo: Placebo matching BI 10773 high dose


Measured Values
   BI 10773 Low (Drug Naive)   BI 10773 High (Drug Naive)   Placebo (Drug Naive)   Sitagliptin 100mg (Drug Naive)   BI 10773 Low (Pioglitazone)   BI 10773 High (Pioglitazone)   Placebo (Pioglitazone)   BI 10773 Low (Metformin)   BI 10773 High (Metformin)   Placebo (Metformin)   BI 10773 Low (Metformin+Sulfonylurea)   BI 10773 High (Metformin+Sulfonylurea)   Placebo (Metformin+Sulfonylurea) 
Participants Analyzed 
[Units: Participants]
 224   224   228   223   165   168   165   217   213   207   225   216   225 
Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment 
[Units: mmHg]
Least Squares Mean (Standard Error)
 -4.9  (0.8)   -4.5  (0.8)   -1.6  (0.8)   -0.2  (0.8)   -1.8  (0.9)   -3.3  (0.9)   0.6  (0.9)   -3.6  (0.7)   -5.2  (0.7)   -0.7  (0.7)   -3.1  (0.7)   -2.7  (0.7)   -0.2  (0.7) 


Statistical Analysis 1 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 Low (Drug Naive) vs. Placebo (Drug Naive)
Method [2] ANCOVA
P Value [3] <0.0001
Adjusted mean difference [4] -4.6
Standard Error of the mean (1.1)
95% Confidence Interval -6.8 to -2.5
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 2 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 High (Drug Naive) vs. Placebo (Drug Naive)
Method [2] ANCOVA
P Value [3] 0.0001
Adjusted mean difference [4] -4.2
Standard Error of the mean (1.1)
95% Confidence Interval -6.4 to -2.1
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 3 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] Placebo (Drug Naive) vs. Sitagliptin 100mg (Drug Naive)
Method [2] ANCOVA
P Value [3] 0.2107
Adjusted mean difference [4] -1.4
Standard Error of the mean (1.1)
95% Confidence Interval -3.5 to 0.8
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 4 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 Low (Drug Naive) vs. Sitagliptin 100mg (Drug Naive)
Method [2] ANCOVA
P Value [3] 0.0033
Adjusted mean difference [4] -3.3
Standard Error of the mean (1.1)
95% Confidence Interval -5.4 to -1.1
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 5 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 High (Drug Naive) vs. Sitagliptin 100mg (Drug Naive)
Method [2] ANCOVA
P Value [3] 0.0105
Adjusted mean difference [4] -2.8
Standard Error of the mean (1.1)
95% Confidence Interval -5.0 to -0.7
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 6 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 Low (Pioglitazone) vs. Placebo (Pioglitazone)
Method [2] ANCOVA
P Value [3] 0.0543
Adjusted mean difference [4] -2.4
Standard Error of the mean (1.3)
95% Confidence Interval -4.9 to 0.0
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 7 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 High (Pioglitazone) vs. Placebo (Pioglitazone)
Method [2] ANCOVA
P Value [3] 0.0019
Adjusted mean difference [4] -3.9
Standard Error of the mean (1.2)
95% Confidence Interval -6.4 to -1.5
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 8 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 Low (Metformin) vs. Placebo (Metformin)
Method [2] ANCOVA
P Value [3] 0.0045
Adjusted mean difference [4] -3.0
Standard Error of the mean (1.0)
95% Confidence Interval -5.0 to -0.9
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 9 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 High (Metformin) vs. Placebo (Metformin)
Method [2] ANCOVA
P Value [3] <0.0001
Adjusted mean difference [4] -4.5
Standard Error of the mean (1.0)
95% Confidence Interval -6.6 to -2.5
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 10 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 Low (Metformin+Sulfonylurea) vs. Placebo (Metformin+Sulfonylurea)
Method [2] ANCOVA
P Value [3] 0.0031
Adjusted mean difference [4] -2.9
Standard Error of the mean (1.0)
95% Confidence Interval -4.8 to -1.0
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 11 for Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
Groups [1] BI 10773 High (Metformin+Sulfonylurea) vs. Placebo (Metformin+Sulfonylurea)
Method [2] ANCOVA
P Value [3] 0.0096
Adjusted mean difference [4] -2.5
Standard Error of the mean (1.0)
95% Confidence Interval -4.4 to -0.6
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.
[4] Other relevant estimation information:
  No text entered.



5.  Secondary:   Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

6.  Secondary:   Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]

7.  Secondary:   Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

8.  Secondary:   Body Weight (kg) Change From Baseline After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]

9.  Secondary:   Body Weight (kg) Change From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

10.  Secondary:   Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]

11.  Secondary:   Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]

12.  Secondary:   Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment   [ Time Frame: Baseline and 52 weeks ]

13.  Secondary:   Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment   [ Time Frame: Baseline and 76 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdf@boehringer-ingelheim.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01289990     History of Changes
Other Study ID Numbers: 1245.31
2010-022718-17 ( EudraCT Number: EudraCT )
Study First Received: January 31, 2011
Results First Received: May 16, 2014
Last Updated: July 14, 2014
Health Authority: Belgium: Federal Agency for Medicinal and Health Products
Canada: Health Canada
China: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Greece: Ethics Committee
India: Drugs Controller General of India
Ireland: Irish Medicines Board
Japan: Ministry of Health, Labor and Welfare
Mexico: Federal Commission for Sanitary Risks Protection
Philippines: Department of Health
Slovakia: State Institute for Drug Control
Slovenia: Agency for Medicinal Products - Ministry of Health
South Korea: Ministry of Food and Drug Safety (MFDS)
Switzerland: Swissmedic
Taiwan:
Turkey: Ministry of Health
Ukraine: State Pharmacological Center - Ministry of Health
United States: Food and Drug Administration